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The adverse outcomes on the oﬀspring from maternal diabetes in pregnancy are substantially documented. In this paper, we
report main knowledge on impacts of maternal diabetes on early and long-term health of the oﬀspring, with speciﬁc comments
on maternal obesity. The main adverse outcome on progenies from pregnancy complicated with maternal diabetes appears to
be macrosomia, as it is commonly known that intrauterine exposure to hyperglycemia increases the risk and programs the
oﬀspring to develop diabetes and/or obesity at adulthood. This “fetal programming”, due to intrauterine diabetic milieu, is termed
as “metabolic memory”. In gestational diabetes as well as in macrosomia, the complications include metabolic abnormalities,
degraded antioxidant status, disrupted immune system and potential metabolic syndrome in adult oﬀspring. Furthermore, there
is evidence that maternal obesity may also increase the risk of obesity and diabetes in oﬀspring. However, women with GDM
possibly exhibit greater macrosomia than obese women. Obesity and diabetes in pregnancy have independent and additive eﬀects
on obstetric complications, and both require proper management. Management of gestational diabetes mellitus and maternal
obesity is essential for maternal and oﬀspring’s good health. Increasing physical activity, preventing gestational weight gain, and
having some qualitative nutritional habits may be beneﬁcial during both the pregnancy and oﬀspring’s future life.
1.Introduction
Compelling evidence exists suggesting that exposure to
an adverse fetal and/or early postnatal environment may
enhance susceptibility to a number of chronic diseases in the
future life of oﬀspring. Gestational diabetes mellitus (GDM)
and obesity are both complications which occur during
pregnancy and substantially inﬂuence the development of
oﬀspring during fetal life and postnatally. Indeed, fetuses
from mothers with gestational diabetes are at high risk of
developing fetal macrosomia [1, 2]. Although most of the
women with GDM return to normal glucose tolerance after
delivery, they have an increased risk of developing diabetes,
mainlytype2diabetesmellitus[3].Oﬀspringofwomenwith
gestational diabetes are prone to adverse side eﬀects such as
macrosomia, which is strongly associated with fetal death,
prematurity,birthtrauma,andrespiratorydistresssyndrome
[4]. These oﬀspring have a high risk of developing obesity,
impaired glucose tolerance, and type 2 diabetes in adulthood
[4]. The concern of most researchers, during the last decade,
is to explore the physiopathology of the relationship between
the health conditions of oﬀspring born from pregnancy
complicated with diabetes. Our team has evidence in many
experimental studies, in which we have observed a high
incidence of macrosomia in the litters of diabetic animals
[1]. The macrosomic (large-sized) oﬀspring of diabetic
animals exhibit many physiological disorders associated with
metabolic syndrome. However, the mechanisms by which
excess maternal weight and/or diabetes during pregnancy
may lead to disease in the oﬀspring at childhood and adult-
hood are not fully understood. The aim of this paper is to
summarize new knowledge on the various physiological and
pathophysiological aspects of early and long-term oﬀspring
outcomes of maternal diabetes during pregnancy. Speciﬁc2 Experimental Diabetes Research
comments on impacts of maternal obesity on oﬀspring
health are also evoked, since the impact of obesity and GDM
on fetus and mother often becomes circular, as the majority
of mothers with GDM are obese and a signiﬁcant proportion
of those who are obese have GDM [5].
2.GestationalDiabetes:MeaningandDiagnosis
Depending on the diagnostic and screening criteria, it has
been observed that prevalence of GDM ranged from 1.3%
to 19.9% [6]. In obesity context, a meta-analysis [7] showed
that the risk of developing GDM was 2.14-fold higher
in overweight pregnant women, 3.56-fold higher in obese
pregnant women, and 8.56-fold higher in severely obese
pregnantwomencomparedtopregnantwomenwithnormal
weight. This analysis prompted the International Association
of Diabetes and Pregnancy Study Groups (IADPSG) to
propose new criteria for the diagnosis of GDM, based on the
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO)
Study [8]. The criteria use a 75-g oral glucose tolerance test
(OGTT) without prior glucose challenge and diagnose GDM
when the fasting glucose is ≥5.1mmol/L and/or when the
1-h postload glucose is ≥10.0mmol/L and/or when the 2-h
postload glucose is ≥8.5mmol/L.
With the greater number of pregnancies complicated
with diabetes, it will be interesting to monitor the long-term
impacts of maternal diabetes in pregnancy on the health
condition of oﬀspring.
3. Macrosomia: The Main Adverse Outcome of
DiabetesinPregnancy
3.1. Studies in Humans. Maternal diabetes is character-
ized by an increased placental transport of glucose and
other nutrients from the mother to the fetus, resulting
in macrosomia [9]. Convincing studies have shown that
either preexisting diabetes (type 1 and type 2 diabetes) or
GDM (diabetes only during pregnancy) are associated with
macrosomia [10–17]. Indeed, epidemiological and clinical
studies have shown that maternal type 1 diabetes during
pregnancy is an important risk factor for fetal overnutrition
and macrosomia and for the development of obesity and
diabetes in oﬀspring [10, 11]. Type 2 diabetes and GDM
are also associated with macrosomia and diabetes in the
progenies [12, 13]. The risk of diabetes in oﬀspring of type
2 diabetes genitors is signiﬁcantly higher when the mother
rather than the father is diabetic [12]. Moreover, the risk
of insulin resistance is higher in children of mothers with
GDM (diabetes only during pregnancy) than in children
from mothers developing diabetes after pregnancy [14].
Macrosomia,themostcommonlyreportedeﬀectofmaternal
diabetes in newborns [15], is usually deﬁned in humans as
b i r t hw e i g h ta b o v ee i t h e r4 k go rb i r t hw e i g h ta b o v et h e
95th percentile of the gestational age. In human studies, 43%
of GDM patients had a macrosomia history [16, 17]. In
total, 75% of the diabetic mothers had an episiotomy during
delivery. Babies from GDM patients whose birth weight was
2.0SD greater than the mean birth weight of control infants
were considered as macrosomic babies.
3.2. Animal Models. In animal studies, the model reported
here concerns streptozotocin-induced type 1 diabetic preg-
nancy which also leads to macrosomia in oﬀspring [18, 19].
Several modes exist for inducing diabetes with streptozo-
tocin. The group of Van Assche has exhaustively investigated
the consequences of experimental maternal diabetes induced
by streptozotocin on fetus and adult progeny [9, 20].
The streptozotocin, when administered at a high single
dose,inducesdiabetesbythedirecttoxiceﬀectsonpancreatic
β-islet cells [9]. The fetus is confronted with severe intrauter-
ine hyperglycemia which induces fetal islet hypertrophy and
β-cell hyperactivity and may result in early hyperinsulinemia
[20]. This overstimulation of fetal β cells limits their
adaptation, and they become depleted of insulin granules
[20], and incapable to secrete insulin [9]. β-cell exhaustion
results in fetal hypoinsulinemia. Hypoinsulinemia and a
reduced number of insulin receptors on target cells lead to
a reduction in fetal glucose uptake [9]. The growth of fetal
protein mass is suppressed, and fetal protein synthesis is
consistently low, leading to fetal microsomia [9]. Postnatal
development is retarded, and these oﬀspring remain small at
adulthood; however, they develop insulin resistance [9, 21].
However, streptozotocin, administered at low doses
during 5 consecutive days, induces mild type 1 diabetes,
following a T-lymphocyte-dependent process, an autoim-
mune destruction of pancreatic β cells, mediated by both
CD4+ and CD8+ T cells [22, 23]. The administration of
low doses of streptozotocin to rodents represents a good
model of diabetes development for several reasons [22,
24, 25]. The intrauterine mild hyperglycemia also induces
fetal hyperinsulinemia with hypertrophy of the endocrine
pancreas and hyperplasia of the β cells [20]. Animals
with perinatal hyperinsulinemia display an impaired glucose
tolerance at adulthood only under high glucose [9].
A model of diabetic pregnancy and macrosomia through
administration to pregnant Wistar rats of ﬁve low doses of
streptozotocinstartingonday5ofgestationisalsowellestab-
lished [1, 26, 27]. Pups from diabetic pregnant rats whose
birth weights were 1.7SD greater than the mean birth weight
of the control pups were considered as macrosomic oﬀspring
[1, 26, 27] .A sf a ra st h em o d e li sc o n c e r n e d ,i ti si m p o r t a n t
to note that maternal streptozotocin administration before
pregnancy aﬀects fertility and impairs embryo development
during preimplantation period [28]. However, the induction
of diabetes by streptozotocin injection on day 5 of gestation
[1]h a sn oe ﬀect on embryo development [19]. We observed
that 62% to 75% of pups born to diabetic pregnant rats
were macrosomic at birth [1, 27, 29]. These macrosomic
(large-sized) oﬀspring of diabetic dams were hyperglycemic
at birth and maintained an accelerated weight gain until the
monitoring time of 12 weeks [26, 30], compared to oﬀspring
of control rats.
Furthermore, maternal hyperlipidemia during diabetic
pregnancy [1] has been shown to be one of the predisposing
f a c t o r so fm a c r o s o m i ai no ﬀspring. In fact, high levels ofExperimental Diabetes Research 3
triglyceride in maternal circulation of diabetic rats may
create a steep concentration gradient across placenta, which
accelerates their transport and deposition in fetal tissues
[31]. In macrosomic oﬀspring, this hypertriglyceridemia
persists with age and is linked to the development of
insulin resistance and hyperlipogenesis [32]. Besides, mater-
nal hyperglycemia also leads to fetal hyperglycemia, which
stimulates pancreatic islet cells and induces fetal hyperinsu-
linemia [26, 27, 32]. The intrauterine hyperinsulinemic state
results in an increase of fat synthesis and body size [33]. The
increase in body weight is a consequence of an increase in
adipose tissue weight and lipid content at all ages.
Thus, macrosomia appears as the main outcome of
maternal diabetes, and both pathologies are associated with
several metabolic disorders, implicating lipid metabolism
and antioxidant status.
4. MainMetabolic Consequences during
MaternalDiabetesandMacrosomia
4.1. Lipid Metabolism Is Altered during Maternal
Diabetes and Macrosomia
4.1.1. Animal Models. As far as lipid metabolism is con-
cerned, experimental diabetes has been shown to impair
maternalandfetallipidmetabolism[31,34].Inexperimental
models, type 1 diabetic pregnancy in rats is associated with
a signiﬁcant increase in serum and hepatic triglyceride (TG)
and total cholesterol (TC) [1, 27, 29]. Macrosomic and obese
oﬀspring of diabetic rats exhibit high adipose tissue weight,
together with high adipose tissue lipid contents [27], and
theyshowhighserumandliverlipidlevels[1,26,29,30].The
hypertriglyceridemia and hypercholesterolemia, common
features of experimental obesity, are the direct consequences
of hyperinsulinemia and hepatic hyperlipogenesis [35, 36].
The major ﬁndings on fatty acid composition in adult
macrosomic oﬀspring were parallel with those of their dia-
betic mothers. Diabetic pregnancy causes a profound decline
in plasma arachidonic acid (AA, C20 :4n-6) and an increase
in linoleic acid (LA, C18 :2n-6) concentrations in rats and in
their macrosomic and obese oﬀspring [1, 29], and this may
be due to an impaired activity of Δ5- and Δ6-desaturases
enzyme [37]. Diabetes-induced low concentration of plasma
AA may have a critical role in maintaining the appropriate
mass and function of islet β cells by inﬂuencing rates of cell
proliferation and insulin secretion [38, 39].
4.1.2. Studies in Humans. Human studies revealed in GDM
patientsthatdiabetesappearedatsecondorthirdtrimesterof
pregnancy [16, 17] as determined by oral glucose tolerance
test according to the World Health Organization criteria.
GDM patients were hyperglycemic and hyperinsulinemic at
the diagnosis of the disease [16, 17], reﬂecting a decrease in
insulin sensitivity in diabetic pregnant women [40]. Several
studiesincludingourshaveshownthat,whencomparedwith
normal values, GDM mothers as well as control mothers
exhibited hypertriglyceridemia and hypercholesterolemia,
throughout pregnancy, and no signiﬁcant diﬀerence exists
between healthy and diabetic women [16, 17, 40–42].
However, macrosomic babies showed high levels of serum
triglyceride and total and free cholesterol compared with
control infants [16, 17].
Thus, maternal diabetes and macrosomia induce an
alteration in lipid metabolism.
4.2. Antioxidant Status Is Aﬀected during Maternal Diabetes
and Macrosomia. One of the earliest abnormalities observed
indiabeticsubjectsistheinvolvementofoxidativestress[43].
Moreover, fetuses from mothers with gestational diabetes are
at increased risk of developing platelet hyperaggregability
and oxidative stress [2]. High blood glucose levels in these
newborns induce oxidative stress [2], which, in turn, induces
the production of highly reactive oxygen radicals, being
toxic to cells, particularly to the plasma membranes where
these radicals interact with the lipid bilayer. Endogenous
antioxidant enzymes (e.g., superoxide dismutase, catalase,
glutathione peroxidase, and reductase) and vitamins are
responsible for the detoxiﬁcation of deleterious oxygen
radicals [44] .I nd i a b e t e sa sw e l la si nm a c r o s o m i a ,p r o t e i n
glycation and glucose auto-oxidation may generate free
radicals, which, in turn, catalyze lipid peroxidation [45].
Moreover, disturbances in the antioxidant defense system
in diabetes and macrosomia have been reported as follows:
alteration in antioxidant enzymes activities [46], impaired
glutathione metabolism [47], and decreased ascorbic acid
levels [48].
4.2.1. Studies in Humans. In human studies [17], we assess
the serum antioxidant status through antiradical resistance
(KRL; Kirial International SA, Couternon, France) and levels
of vitamin A, C, and E and activity of superoxide dismutase
(SOD). GDM as well as macrosomia induce an altered total
serum antioxidant defense status [17]. Indeed, gestational
diabetic women exhibit decreased levels of vitamin E and
enhanced concentrations of vitamin C without any changes
in vitamin A. Macrosomia also induces decreased levels
of vitamin E. GDM and macrosomia are also associated
with impaired SOD activities and enhanced levels of serum
thiobarbituricacid-reactivesubstances(TBARSs),suggesting
an increased oxidative stress [17].
4.2.2. Animal Models. In experimental model [1], type 1
diabetic pregnancy and macrosomia lead to a signiﬁcant
decrease in the plasma total antioxidant status as measured
by diminished plasma oxygen radical absorbance capacity
(ORAC) in diabetic pregnant rats and their macrosomic
pups [1]. We have also observed increased plasma TBARS,
decreased erythrocyte superoxide dismutase and glutathione
peroxidase activities in diabetic rats and their macrosomic
oﬀspring, and diminished vitamin A levels in diabetic dams
and vitamin C concentrations in macrosomic pups. Several
authors have also shown diminished antioxidant enzyme
activities and vitamin levels in streptozotocin-induced dia-
betic rats [46–48].4 Experimental Diabetes Research
Tosumup,inanimalsaswellasinhumans,maternaldia-
betesandmacrosomiaareassociatedwithalteredantioxidant
status [1, 17].
5.IsNeonatal ObesityProgrammed
duringIn Utero Life? New Concept of
a“Metabolic Memory”
The hypothesis on fetal origin suggests that the fetal malnu-
trition, which, during pregnancy, induces disruption in fetal
growth and thinness at birth, programs latter type 2 diabetes
and metabolic syndrome [49]. At critical and delicate period
of fetal development, the process by which a stimulus
induces long-term impacts on fetus, previously described
and established as “fetal programming” by Hales and Barker
[49], is termed as new concept of “metabolic memory.” In the
same line, all the observed metabolic abnormalities among
gestational diabetic women create an in-utero environment
around the fetus which programs him to diseases during
his adulthood [49, 50]. This in utero programming seems
to create a kind of “metabolic memory,” since physiological
anomalies of gestational period are responsible for the
onset of diseases in oﬀspring at adulthood, such as type 2
diabetes and obesity associated with metabolic syndrome. It
is noteworthy that several alterations in carbohydrate and
lipid metabolism, observed in infants of diabetic mothers
at birth, also persist postnatally. As an example of this
phenomenon of metabolic memory, we can mention a study
of Palinski and Napoli [51] who demonstrated that maternal
hypercholesterolemia during pregnancy is associated with
greatly increased fatty streak formation in human fetal
arteries and acceleratedprogression of atherosclerosisduring
childhood [51]. A good correlation exists between maternal
and fetal plasma cholesterol levels in 5-6-month-old human
fetuses [52, 53]. Moreover, maternal hyperglycemia has
been shown to lead to fetal hyperglycemia which stimulates
fetal pancreatic islet cells to produce fetal hyperinsulinemia
[54]. The ability of fetal hyperinsulinemia to increase the
availability of farnesylated p21-Ras may represent one of
mechanisms of the growth-promoting action of insulin
during fetal development [55].
Another example of metabolic memory is revealed by
Franke et al. [56] who have shown that diabetic pregnancy
in rats alters the diﬀerentiation of hypothalamic neurons
of newborns (Figure 1). The alterations of hypothalamic
neurons may be avoided by normalizing the glycemia
among diabetic pregnant rats [56]. The increased levels
of neuropeptide-Y (Figure 1)i no ﬀspring of hyperglycemic
rats may be explained by a defected programming of the
hypothalamic neurons, due to intrauterine environment
of gestational diabetic milieu [56]. These alterations may
increase the risk of trend in high food taking, overweight,
obesity, and diabetogenic status in oﬀspring at adulthood
(Figure 1). All these observations prove an in utero program-
ming of metabolic syndrome in oﬀspring born to maternal
diabetes.
6. Modulation of InsulinResistance
andInﬂammation duringMaternalDiabetes
andMacrosomia
Gestational diabetes and obesity are two pathologies asso-
ciated with insulin resistance and inﬂammation which are
profoundly modulated by adipokines and cytokines [16].
Obesity is associated with high adiposity and hyperlipidemia
[57]. Moreover, low-grade inﬂammation has been reported
to be a link between insulin resistance, obesity, and type
2 diabetes [57]. Thus, it appears that inﬂammation may
modulate insulin resistance in GDM.
6.1. Studies in Humans. There is evidence that hypoad-
iponectinemia is associated with pathogenesis of GDM
and macrosomia [58]. Adipokines and cytokines, through
their ability to interfere with insulin signaling, have been
implicated in insulin resistance [59]. Adiponectin, a physi-
ologically active polypeptide hormone derived from adipose
tissue, exhibits insulin-sensitizing, antiatherogenic, and anti-
inﬂammatory properties [60].
In human studies, we and other investigators have
shown that women with GDM, compared with non-
diabetic women, exhibited a decreased concentration of
adiponectin (anti-inﬂammatory agent) [16, 61], concomi-
tant with an increased concentration of TNF-α and IL-6
(pro-inﬂammatory cytokines) [16]. Is there any physiologi-
cal crosstalk between the high levels of TNF-α and the low
adiponectin concentrations in women with GDM? It has
been shown that adiponectin and TNF-α produce opposite
eﬀects on insulin signaling, with inhibiting action of TNF-α
[62] and increasing action of adiponectin [63] on tyrosine
phosphorylation of the insulin receptor. Besides, it is also
possiblethatTNF-αmayberesponsibleforloweredsynthesis
of adiponectin in GDM subjects, as suggested by Lihn et
al. [64] that TNF-α and IL-6 downregulate adiponectin
expression (Figure 1). Regarding the long-term eﬀect on the
oﬀspring of gestational diabetic women, it is important to
mention the study of Tsai et al. [65], who have demonstrated
that decreased maternal adiponectin concentration and
insulin sensitivity may increase the risk of fetal overgrowth
in women suﬀering from GDM. However, our study revealed
that concentrations of TNF-α, IL-6, adiponectin, and leptin
are decreased in macrosomic babies compared to control
infants [16]. Furthermore, IL-6 has been shown to be one
of the mediators of hyperinsulinemic state [66], 10%−35%
of the body’s basal circulating IL-6 is derived from adipose
tissue, and a positive correlation has been found between
insulin resistance and circulating IL-6 [57].
Leptin is not only produced by the placenta but prin-
cipally by the adipocytes, secreted into the bloodstream
[67], and involved in weight gain regulation and lipid
metabolism. Leptin is an appetite-suppressant agent, and
it exerts its eﬀects by interacting with neuropeptide-Y in
the hypothalamus (Figure 1)[ 68]. Contradictory results
have been reported about leptin secretion during GDM
and macrosomia. GDM is either associated with high levels
of leptin [69], no change [70], or reduced level of leptinExperimental Diabetes Research 5
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Figure 1: In GDM, adipose tissue secretes low adiponectin (anti-inﬂammatory and positive stimulator of insulin sensitizing) and high
TNF-α and IL-6 which contribute to inﬂammatory state and insulin resistance in diabetic pregnancy as well as in macrosomia. Leptin, being
pro-inﬂammatory, is highly produced by adipose tissue during diabetic pregnancy and insulin resistance (experimental study [75]) and
implicated in the pathogenesis of weight gain in macrosomic babies. Leptin may exert its eﬀects by interacting with neuropeptide-Y in the
hypothalamus. The intrauterine hyperglycemia may act on the fetal hypothalamus and create a kind of “metabolic memory” which programs
obesity and metabolic syndrome in the oﬀspring during adulthood. (+) positive regulation (−) negative regulation. NPY, neuropeptide-Y.
[71]. Our previous reports have shown high leptin level
in mothers with GDM and reduced level of leptin in their
macrosomic infants [16]. This discrepancy could be a result
ofthediﬀerenceinthetimeofmaternalbloodcollection(i.e.,
gestational age). However, elevated leptin concentrations
during diabetic pregnancy may be due to its secretion by
adipocytes in presence of elevated estrogen [72]a n db y
placenta [73]. In fact, leptin, acting as a signal for suﬃcient
energy supply, is persistently increased in women with GDM
after delivery and associated with hyperglycemia and insulin
resistance [69]. Hence, leptin, as a pro-inﬂammatory factor,
may contribute to the inﬂammatory state during gestational
diabetes. In contrast, low leptin level in macrosomic babies
may contribute to the weight gain, since leptin-deﬁcient
rodents [68]a n dh u m a n[ 74] have been shown to develop
obesity.
6.2. Animal Models. In order to investigate the relation-
ship between insulin resistance and inﬂammation along
with the obesity-related parameters such as adiponectin
and leptin and pro-inﬂammatory markers, we have very
recently undertaken a study in insulin-resistant oﬀspring
born to streptozotocin-induced diabetic pregnant mice [75].
Adiponectin and leptin expression is positively correlated
with the epididymal adipose tissue mass which decreases
in insulin-resistant oﬀspring of diabetic mice [75]. Hence,
reduced adiponectin contributes to insulin resistance as this
adipokine, an anti-inﬂammatory agent, has been shown
to enhance insulin sensitivity [63, 76]. Insulin resistance
induces high expression of IL-6 and TNF-α mRNA in
epididymal adipose tissue [75]. Adipose tissue secrete IL-
6a n dT N F - α during insulin resistance [77], and high
levels of TNF-α and IL-6 may downregulate the expression
of adiponectin [64]( Figure 1). During insulin resistance,
increased IL-6 might not only diminish insulin sensitivity
by suppressing insulin signal transduction but also interfere
with anti-inﬂammatory eﬀect of insulin, and might favour
inﬂammation during insulin resistance [57].
All these clinical and experimental observations suggest
that TNF-α and IL-6 may be involved in the pathogenesis6 Experimental Diabetes Research
of insulin resistance, and there is a positive correlation
between insulin resistance and inﬂammation in GDM and
macrosomia.
7. ImmuneSystemModulationduringMaternal
DiabetesandMacrosomia
There is a growing body of evidence that suggests the
implication of a pathological role of immune system and
inﬂammation in type 1 diabetes, type 2 diabetes, and
GDM. Indeed, T-cell-derived cytokines are involved in the
autoimmune destruction of pancreatic islet cells leading to
type1diabetes[22]whereastype2diabetesisassociatedwith
a generalized activation of innate immune system, in which
there is a chronic, cytokine-mediated state of low-grade
inﬂammation [78–80]. Moreover, evidence from human and
experimental models suggests that a shift between Th1 and
Th2 cells may modulate the severity of type 1 diabetes
[22, 41], in which Th1 cytokines are highly produced during
the islet inﬂammatory response and may partially explain
the ability of CD4+ T cells to cause β-cell destruction [23].
In the nonobese diabetic (NOD) mouse, the most common
animal model of human type 1 diabetes, it is observed an
autoimmune destruction of pancreatic β cells, mediated by
both CD4+ and CD8+ T cells [23].
Besides, in normal pregnancy, Th1 cytokines are down-
regulated, whereas Th2 cytokines are upregulated [81, 82],
in animals as well as in humans. Even though the induction
of type 1 diabetes is closely associated with high expression
of Th1 cytokines, IFN-γ in particular [81], experimental
and clinical studies reveal that, in pregnancy complicated
with type 1 diabetes, Th1 cytokines are downregulated in
diabetic pregnant rats and in women with GDM [16, 29].
Type 1 diabetic pregnancy in rats and GDM in women also
induce increased level of IL-10, a Th2 cytokine [16, 29]. The
level of IL-4 (another Th2 cytokine) is either decreased in
diabetic animals [16, 83] or unchanged in GDM patients
[16], due to the presence of diabetes [25]. Diminished Th1
cytokines and increased IL-10 (a Th2 cytokine) may be
implicated in maintaining the pregnancy in diabetic rats
and GDM patients (Figure 2). In fact, the shift of Th1/Th2
ratio to a protective Th2 phenotype during pregnancy (in
animal and humans) has been shown to encourage vigorous
production of antibodies which not only combat infections
during pregnancy but also oﬀer passive immunity to fetus
[84]. On the other hand, the downregulated Th1 proﬁle
in diabetic pregnant animals and GDM patients (associated
with successful pregnancy) may be contributed by elevated
levels of reproductive hormones like hCG (human chorionic
gonadotrophin) whose administration is known to diminish
the production of Th1 cytokines [85].
As far as macrosomia is concerned, evidence in animals
and humans reveals that macrosomia and obesity are asso-
ciated with the shift of Th1/Th2 ratio to the Th1 phenotype
[16, 29].
To sum up, it is interesting to note that diabetes during
pregnancy in animals and human shifts the balance of
Th1/Th2 cells to a protective Th2 phenotype, whereas,
in macrosomic and obese oﬀspring of diabetic dams, the
Th1/Th2 balance is shifted to a pro-inﬂammatory Th1
phenotype (Figure 2). This upregulated Th1 proﬁle in obese
oﬀspring may confer to these animals a potential pro-
inﬂammatory and “diabetogenic status,” as revealed by
the hyperglycemia and hyperinsulinemia observed in these
animals in adulthood [27]. All these observations presume
the long-term eﬀects of maternal diabetes on the health of
the oﬀspring during their adulthood.
8.Problems AssociatedwithObesityand
DiabetesduringPregnancy
The prevalence of obesity is increasing across the world [86].
Using the WHO criteria, obesity can now be deﬁned by
three grades of severity: grade I obesity with 30 ≤ BMI ≤
34.9kg/m2, grade II or severe obesity with 35 ≤ BMI ≤
39.9kg/m2, and grade III or massive obesity with BMI ≥
40kg/m2.O v e r w e i g h ti sd e ﬁ n e da s2 5≤ BMI ≤ 29.9kg/m2.
PeoplewhoseBMIiscomprisedbetween18.5and24.9kg/m2
are considered as being normal weight (subjects with a BMI
below 18.5kg/m2 are considered as being underweight).
Obesitypandemicisaﬀecting all groups of age, including
children, adolescents, young adults, and adults [87, 88].
Consequently, there are a growing number of obese women
who are becoming pregnant.
To an extent, obesity epidemic is explained by the
increase in availability and consumption of energy-dense
foods and a reduction in physical activity. However, there
are additional putative factors which may explain the entire
explosion in obesity prevalence [89]. These putative contrib-
utors operate through genetic factors, reproductive behav-
iors, and/or the intrauterine milieu, matters of importance
for those involved with obesity and diabetes in pregnancy
[89].
Naturally in normal pregnancy, there is a physiological
trend of insulin resistance from the second trimester. But in
context of obesity, hyperinsulinemia associated with insulin
resistance leads to the occurrence of GDM [90]. Moreover,
it is known that obesity is linked to high adiposity and
hyperlipidemia[57];however,centralfat,ratherthanperiph-
eral adiposity, is more associated with insulin resistance, a
predisposing factor to GDM [91, 92].
On the other hand, some investigators have recently
found that maternal weight gain during pregnancy increases
the oﬀspring birth weight and the oﬀspring’s risk of obesity
later in life, independently of genetic factors [93]. Similarly,
Roman et al. [94] have found that maternal obesity was
signiﬁcantly associated with complications on the mother
as well as on her baby: maternal obesity leads to the
need for oral hypoglycemic agents or insulin, development
of pregnancy-related hypertension, interventional delivery,
and cesarean delivery. Adverse neonatal outcomes were
also signiﬁcantly increased including stillbirth, macrosomia,
shoulder dystocia, hypoglycemia, and jaundice [94]. How-
ever, recent investigations report that macrosomia appears
to be the predominant adverse outcome in cases of GDMExperimental Diabetes Research 7
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Figure 2: Na¨ ıve CD4+ T-helper (Th0) cells can be diﬀerentiated into either Th1 cells, producing pro-inﬂammatory cytokines (IL-2, IL-
12, IFN-γ) or Th2 cells, secreting anti-inﬂammatory cytokines (IL-4, IL-10, IL-5, IL-13). In normal pregnancy as well as in diabetic
pregnancy, the Th1/Th2 balance shifts towards a protective Th2 phenotype, whereas it shifts towards a pro-inﬂammatory Th1 phenotype in
macrosomiaaswellasinobesity.Moreover,reproductivehormonelikehCGmaycontributetothelowTh1phenotypeindiabeticpregnancy
associated with the successful pregnancy. Th, T helper cells; hCG, human chorionic gonadotrophin; GDM, gestational diabetes mellitus; (+)
upregulation; (−) downregulation.
[15]. Maternal obesity is an additional risk factor for
complications, regardless of diabetes status [15].
To sum up, there are diﬀerences between women with
GDM and obese women in pregnancy, as women with GDM
possibly have greater macrosomia (even after treatment).
There is clearly far greater neonatal hypoglycemia and
jaundice among the oﬀspring of women with GDM than
thosefromobesewomen,butthisobservationandotherdata
havetobeinterpretedwithcautionassomewomenmayhave
had undiagnosed preexisting diabetes [5].
9. Management of Long-Term Impact
of MaternalObesity andDiabeteson
theOffspring
Only few studies are available on pregnancy intervention for
maternal diabetes and obesity during pregnancy. Weight loss
may not be recommended during pregnancy [95]. However,
evidence suggests that obesity’s surgery-associated weight
loss may be linked to less obesity in the oﬀspring [96]. The
outcomes of pregnancy complicated with maternal obesity
or preexisting diabetes (mainly type 1 and type 2 diabetes,
including undiagnosed type 2 diabetes) and GDM depend
upon the intensity of treatment. Some studies show that
treatment of GDM appears to reduce the risk of postpartum
depression symptoms in the mothers [97]. Untreated GDM
may be associated with a 2-fold risk of increased weight
in oﬀspring at 5–7 years [98]. Some observations show
that more intensive treatment with insulin in GDM might
be associated with less adiposity in oﬀspring by 2 years
8 months [99]. However, randomized clinical studies of
the management of GDM showed that treatment of GDM
reduced macrosomia at birth, but did not show a reduction
in BMI at the age 4-5 years [15, 100].
Nutritional strategies have also been proposed, since
experimental and clinical evidence prove the beneﬁcial
eﬀects of omega-3 fatty acid consumption during dia-
betes [101, 102]. Epidemiological studies have shown low
incidence of inﬂammatory diseases in Greenland Eskimos8 Experimental Diabetes Research
and Japanese people [103], and this is attributed to large
consumption of cold water marine ﬁsh that contain omega-
3 fatty acids [104, 105]. In experimental studies, omega-
3 fatty-acid enriched diet improves the hyperlipidemia
induced by diabetic pregnancy and macrosomia [1, 27, 34].
Diabetic pregnancy and macrosomia are associated with
increased oxidative stress (see above), and omega-3 fatty acid
consumptionalsorestoresthedecreasedantioxidantstatusof
diabetic pregnant animals and their macrosomic and obese
oﬀspring [1]. Moreover, omega-3 fatty acid enriched-diet
exerts beneﬁcial eﬀects on immune system by promoting
a protective Th2 phenotype during diabetic pregnancy and
macrosomia [29]. Consumption of omega-3 fatty acid also
prevents long-term metabolic abnormalities associated with
macrosomia [27, 34].
Furthermore, many studies have reported that dietary
supplements by vitamins and minerals prevent or, at least,
attenuate organic deterioration caused by an excessive
oxidative stress in diabetic subjects [106, 107]. As regards
recentobservations thatmany obese womenareserologically
vitamin D deﬁcient, it is now recommended in the UK that
Vitamin D supplementation may be provided for all women
with a prepregnancy BMI of 30kg/m2 [108].
10. Conclusion
Maternal diabetes or obesity during pregnancy appears to
be an important risk factor for fetal obesity or macrosomia.
Alterations in macrosomic infants persist postnatally and
conduct to several abnormalities including the development
of insulin resistance, obesity, diabetes, and metabolic syn-
drome at adulthood. Management of GDM and maternal
obesity, including nutritional strategies, may have real
improvement on maternal health and oﬀspring in the future
life.
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